CDMO Expansion PSI is expanding from local to international injectable manufacturing, supported by a recent partnership with AmpleLogic to extend CDMO capabilities across multiple contract manufacturing sites. This presents a sales opportunity to offer regulatory intelligence, platform integration, and validation support services, as well as market expansion solutions for PSI's growing footprint.

Regulatory Excellence PSI adheres to SFDA GMP and ISO 13485, with US and British pharmacopeia alignment, indicating a strong compliance baseline. This creates a sales opening for advanced QA, audit readiness services, import/export compliance tooling, and GMP training programs that resonate with their regulatory-forward approach.

IV and Injectable Focus The company is a leading player in IV solutions and injectable products in the MENA region. Opportunities exist to offer specialized formulation development, sterile manufacturing enhancements, fill-finish capacity planning, and equipment modernization to support scalable injectable production.

Digital and Analytics PSI’s technology stack includes SAP, Excel, WordPress and other tools, indicating an openness to enterprise software, data analytics, and ERP/CRM optimization. Propose integrated digital transformation, ERP optimization, regulatory documentation management, and data-driven quality systems to improve efficiency across sites.

Growth and Partnerships With revenue in the multiple tens of millions and a strategic JV-like partnership with AmpleLogic to provide platform, validation, and regulatory intelligence, PSI represents a scalable customer for solutions in training, documentation, regulatory intelligence, and site-wide validation programs that can be bundled with ongoing CDMO services.